naloxegol

01/01/2023 - "This study evaluates the onset, magnitude, and consistency of improvement of opioid-induced constipation (OIC) symptoms with naloxegol treatment. "
10/01/2017 - "Population Exposure-Response Modeling Supported Selection of Naloxegol Doses in Phase III Studies in Patients With Opioid-Induced Constipation."
09/01/2013 - "A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation."
11/15/2023 - "Naloxegol has been shown to be an efficient alternative to treat opioid-induced constipation (OIC). "
07/01/2023 - "Naloxegol for Treatment of Opioid-Induced Constipation in the Pediatric Intensive Care Unit."

02/01/2015 - "Phase II and Phase III studies in patients with non-cancer OIC have confirmed the efficacy of naloxegol to inhibit OIC, and the most consistent efficacy was seen with the 25 mg dose once daily. "
11/01/2014 - "Phase II and Phase III studies in patients with non-cancer OIC confirmed the efficacy of naloxegol to inhibit OIC, and the most consistent efficacy was seen with the 25 mg dose once daily. "
03/11/2021 - "The results of this first long-term and real-world-data study in patients with cancer, showed the sustained efficacy and safety of naloxegol for the treatment of OIC in this group of patients."
03/11/2021 - "The main objective was to analyse the long-term efficacy, quality of life (QOL) and safety of naloxegol in patients with cancer in a real-world study. "
03/01/2021 - "The objectives of this study were to assess quality of life as well as efficacy and safety of naloxegol, in patients with cancer with OIC. "

10/01/2015 - "Other SBM measures, daily symptoms of OIC, and both the Patient Assessment of Constipation - Symptoms and Patient Assessment of Constipation-Quality of Life scores improved from baseline with naloxegol treatment. "
11/15/2023 - "Augmentation with another constipation medication was relatively common, suggesting that naloxegol was used for multifactorial constipation. "
11/15/2023 - "Approximately 10%-30% switched to or augmented the treatment with another constipation medication or restarted naloxegol after discontinuation. "
01/01/2016 - "These analyses suggest that treatment with naloxegol improves patients' health state utility; driven predominantly by the relief of patients' constipation. "
12/01/2021 - "Correction to: Effectiveness of naloxegol in patients with cancer pain suffering from opioid‑induced constipation."

07/01/2023 - "Conclusion Naloxegol showed promising safety and efficacy profiles in treating OIC amongst critically ill patients, though our findings require further validation through prospective studies. "
07/01/2023 - "Evaluating the Safety and Efficacy of Naloxegol in Critically Ill Opioid-Induced Constipation Patients."
07/01/2023 - "We performed a retrospective analysis of critically ill children that had received naloxegol for opioid-induced constipation at our institution. "
04/01/2021 - "The goal of this study was to evaluate the effectiveness and safety of methylnaltrexone and naloxegol in hospitalized children, including those with critical illness. "
07/01/2023 - "This suggests naloxegol is effective in increasing stool output in critically ill children receiving opioids without an increase in opioid-withdrawal symptoms. "

01/01/2018 - "Comprehensive CV safety analyses were performed in 4 clinical studies of naloxegol (12.5 and/or 25 mg) in patients with noncancer pain and OIC: two 12-week, double-blind, randomized studies; a 12-week, double-blind, extension study; and a 52-week, randomized, open-label study versus usual care. "
01/01/2018 - "Two phase 3 randomized, double-blind, 12-week studies evaluated the efficacy and safety of oral naloxegol (12.5 or 25 mg daily) in adults (18 to < 85 years) with confirmed OIC and chronic noncancer pain: KODIAC-04 (NCT01309841) and KODIAC-05 (NCT01323790). "
11/01/2016 - "Naloxegol was generally safe and well tolerated in this 12-week extension study in patients with noncancer pain and OIC."
09/01/2016 - "Efficacy (bowel movement in 42-49% of patients not responsive to laxatives) and safety of naloxegol were confirmed in studies conducted in patients with OIC and nonmalignant pain. "
01/01/2018 - "Respective mean ± SD changes from baseline average pain for placebo, naloxegol 12.5 mg, and naloxegol 25 mg were -0.2 ± 1.07, -0.3 ± 1.05 (P = 0.773 vs. placebo), and 0.2 ± 0.95 (P = 0.837 vs. placebo; KODIAC-04) and -0.1 ± 0.94, -0.1 ± 0.87 (P = 0.744), and 0.0 ± 1.18 (P = 0.572; KODIAC-05). "